Articles

ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial

Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK
Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK
Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK
Department of Haematology, Royal Bournemouth Hospital, Bournemouth, UK
Cancer Research Center (IBMCC-CSIC), University of Salamanca, Spain
Centre for Medical Oncology, Barts and The London School of Medicine and Dentistry, London, UK
Department of Haematology, Royal Bournemouth Hospital, Bournemouth, UK
Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK
Human Development and Health, Faculty of Medicine, University of Southampton, UK
Centre for Medical Oncology, Barts and The London School of Medicine and Dentistry, London, UK
School of Cancer Sciences, University of Birmingham, UK
Haemato-oncology Research Unit, Division of Molecular Pathology, The Institute for Cancer Research, Sutton, UK
School of Cancer Sciences, University of Birmingham, UK
Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK;Department of Haematology, Royal Bournemouth Hospital, Bournemouth, UK
Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK
Vol. 99 No. 4 (2014): April, 2014 https://doi.org/10.3324/haematol.2013.098574